Chemoinformaics analysis of all-trans-Neoxanthin
| Molecular Weight | 600.884 | nRot | 9 |
| Heavy Atom Molecular Weight | 544.436 | nRig | 24 |
| Exact Molecular Weight | 600.418 | nRing | 3 |
| Solubility: LogS | -5.855 | nHRing | 1 |
| Solubility: LogP | 7.618 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 100 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 44 | No. of Aromatic Carbocycles | 0 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 56 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 40 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 107.348 |
| nHD | 3 | BPOL | 57.9156 |
| QED | 0.141 |
| Synth | 5.519 |
| Natural Product Likeliness | 2.207 |
| NR-PPAR-gamma | 0.016 |
| Lipinski | Rejected |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 1 |
| Pgp-sub | 0.893 |
| HIA | 0.167 |
| CACO-2 | -5.09 |
| MDCK | 0.0000184 |
| BBB | 0.366 |
| PPB | 0.978583 |
| VDSS | 3.098 |
| FU | 0.0312727 |
| CYP1A2-inh | 0.003 |
| CYP1A2-sub | 0.316 |
| CYP2c19-inh | 0.073 |
| CYP2c19-sub | 0.942 |
| CYP2c9-inh | 0.207 |
| CYP2c9-sub | 0.094 |
| CYP2d6-inh | 0.013 |
| CYP2d6-sub | 0.615 |
| CYP3a4-inh | 0.182 |
| CYP3a4-sub | 0.949 |
| CL | 2.156 |
| T12 | 0.355 |
| hERG | 0.803 |
| Ames | 0.658 |
| ROA | 0.207 |
| SkinSen | 0.985 |
| Carcinogencity | 0.52 |
| EI | 0.015 |
| Respiratory | 0.861 |
| NR-Aromatase | 0.935 |
| Antiviral | Yes |
| Prediction | 0.663867 |